Aliskiren Angiotensin II type 1 receptor blocker Direct renin inhibitor Hypertension Losartan Oxidative stress Reactive oxygen species A B S T R A C T Renin-angiotensin system activation promotes oxidative stress and endothelial dysfunction. However, no previous study has examined the effects of the renin inhibitor aliskiren, either alone or combined with angiotensin II type 1 antagonists on alterations induced by two-kidney, one-clip (2K1C) hypertension. We compared the vascular effects of aliskiren (50 mg/kg/day), losartan (10 mg/kg/day), or both by gavage for 4 weeks in 2K1C and control rats. Treatment with losartan, aliskiren, or both exerted similar antihypertensive effects. Aliskiren lowered plasma Ang I concentrations in sham rats and in hypertensive rats treated with aliskiren or with both drugs. Aliskiren alone or combined with losartan decreased plasma angiotensin II concentrations measured by high performance liquid chromatography, whereas losartan alone had no effects. In contrast, losartan alone or combined with aliskiren abolished hypertension-induced increases in aortic angiotensin II concentrations, whereas aliskiren alone exerted no such effects. While hypertension enhanced aortic oxidative stress assessed by dihydroethidium fluorescence and by lucigenin chemiluminescence, losartan alone or combined with aliskiren, but not aliskiren alone, abolished this alteration. Hypertension impaired aortic relaxation induced by acetylcholine, and losartan alone or combined with aliskiren, but not aliskiren alone, reversed this alteration. Losartan alone or combined with aliskiren, but not aliskiren alone, increased plasma nitrite concentrations in 2K1C rats. These findings show that antihypertensive effects of aliskiren do not prevent hypertension-induced vascular oxidative stress and endothelial dysfunction. These findings contrast those found with losartan and suggest that renin inhibition is not enough to prevent hypertension-induced impaired redox biology and vascular dysfunction.
Introduction
Renovascular hypertension is a major cause of secondary hypertension, whereas metabolic and endocrine causes are less frequent (Lerman et al., 2005) . The chronic renal artery stenosis promotes activation of the renin-angiotensin system, thus contributing to accelerated target organ damage (Campos et al., 2015) . For this reason, using nongenetic experimental animal models of renovascular hypertension may be very useful to address this disease and associated end-organ damage (Lerman et al., 2005) .
Enhanced activity of the renin-angiotensin system plays a critical role in the pathogenesis of hypertension (Te Riet et al., 2015) . This is so relevant that numerous studies have shown pharmacological modulation of this system as an important therapeutic strategy in the management of arterial hypertension. Particularly, the use of angiotensin converting enzyme inhibitors or antagonists of angiotensin type 1 (AT 1 ) receptor decreases the incidence of fatal and non-fatal cardiovascular outcomes (Dahlof et al., 2002) .
Most deleterious effects caused by renin-angiotensin system activation has been attributed to the remarkable ability of angiotensin II (Ang II) to stimulate multiple intracellular signaling pathways implicated in target organ damage. Compelling results have shown that stimulation of AT 1 receptor contributes to cellular hypertrophy, proliferation and migration (Higuchi et al., 2007) , increased vascular tone (Nguyen Dinh Cat et al., 2013) , enhanced reactive oxygen species generation and endothelial dysfunction (Hitomi et al., 2007) . In agreement with these observations, in vitro studies revealed that Ang II activates nicotinamide adenine dinucleotide phosphate [NAD(P)H] oxidase, which is a major source of vascular reactive oxygen species (Laplante et al., 2003) . Indeed, augmented concentrations of reactive oxygen species have been consistently reported in experimental models of hypertension (Amaral et al., 2015; Castro et al., 2009 ). In addition, NAD(P)H oxidase up-regulation and increased reactive oxygen species production were found in vascular smooth muscle cells from resistance arteries of hypertensive patients, and this alteration may directly contribute to endothelial dysfunction and maintenance of the hypertensive process (Touyz and Schiffrin, 2001) .
Renin-angiotensin system activation promotes vascular reactive oxygen species production, which impairs nitric oxide (NO) bioavailability and result in endothelial dysfunction (Nguyen Dinh Cat et al., 2013) . In agreement with this mechanism, there is strong evidence supporting the idea that some blockers of the renin-angiotensin system exert antioxidant effects (Weseler and Bast, 2010) . Indeed, AT 1 receptor antagonists and the renin inhibitor aliskiren were shown to decrease vascular levels and to increase the expression of endothelial NO-synthase, thus improving vascular NO levels and restoring the endothelial function in hypertensive rats (Ceravolo et al., 2014; Cosentino et al., 2005; Savoia et al., 2013; Yamamoto et al., 2009 ). However, no previous study has examined the effects of the direct renin inhibitor aliskiren associated with the AT 1 receptor antagonist losartan on the functional alterations induced by two-kidney, one-clip (2K1C) hypertension.
The classical model of renovascular hypertension, two-kidney, one clip (2K-1C) is associated with marked increases in plasma renin activity and systemic/tissue angiotensin II levels contributing to increase oxidative stress. In the present study, we compared the effects of longterm administration of aliskiren, losartan, or the combination of these drugs on vascular dysfunction found in 2K1C hypertension, which is associated with Ang II-stimulated reactive oxygen species generation.
Materials and methods

Animals and treatments
This study complied with guidelines of the Ribeirao Preto Medical School, University of Sao Paulo (Animal Ethics Committee approval number 1962008), and the animals were handled according to the guiding principles published by the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Male Wistar rats (180-200 g) obtained from the colony at University of Sao Paulo were maintained on 12-h light/dark cycle at 25°C with free access to rat chow and water.
2K1C hypertension was induced by clipping the left renal artery with a silver clip (0.2 mm) . Sham-operated rats underwent the same surgical procedure under general anesthesia with ketamine 100 mg/kg and xylazine 10 mg/kg i.p., except for the placement of the renal artery clip. The systolic blood pressure (SBP) was measured using tail-cuff plethysmography in conscious rats weekly throughout the experiment period. The rats were considered as hypertensive when SBP was higher than 160 mmHg two weeks after the surgery.
A total de 80 animals were randomly assigned to one of eight groups (n = 10/group): 2K1C and sham groups that received water; 2K1C and sham groups that received losartan (LOS; Cozzar®, Merck Sharp& Dohme) at 10 mg/kg −1 day −1 per day (Brassard et al., 2005) ; 2K1C
and sham groups that received aliskiren (ALK; Rasilez®, Novartis) at 50 mgkg −1 day −1 per day (Nussberger et al., 2008) and 2K1C and sham groups that received the combination of drugs (ALK/LOS). The treatments were started two weeks after 2K1C hypertension was induced and maintained for additional four weeks. The drugs were administered daily by oral gavage and distilled water was used as vehicle.
At the end of the experimental period, animals were anesthetized as described above and killed by decapitation. Arterial blood samples were centrifuged at 1000×g for 10 min and plasma fraction was immediately stored at − 70°C until used for biochemical measurements. The thoracic aorta was removed and stored at − 70°C.
Vessel ring preparation and vascular reactivity
After 6 weeks of treatment with vehicle, aliskiren and/or losartan, the animals were killed by decapitation and their thoracic aortas were quickly removed and cleaned of adherent connective tissue. Aortic rings, 4 mm in length, were cut and mounted for isometric tension recording (Oliveira-Paula et al., 2016) . The rings were placed in bath chambers (5 mL) for isolated organs containing modified Krebs salt solution containing (mM): NaCl 130, CaCl 2 1.6, MgSO 4 1.2, KH 2 PO 4 1.2, KCl 4.7, NaHCO 3 14.9, glucose 5.5, which was maintained at 37°C and pH 7.4, and bubbled with 95% O 2 and 5% CO 2 . The system was connected to an isometric force displacement transducer (TRI201, Panlab, Barcelona Spain) and the responses were recorded on a computer system using the Chart Pro 5 (PowerLab, ADInstruments, Sydney, Australia). The aortic rings were subjected to a basal tension of 1.5 g during 60 min equilibration period with the bath fluid being changed every 15-20 min. Endothelial integrity was assessed qualitatively examining the degree of relaxation caused by acetylcholine (Ach, 10 −6 M) in the presence of contractile tone induced by phenylephrine (10 −7 M). The aortic ring was used if relaxation induced by Ach was 70% or greater. The aortic rings were precontracted by phenylephrine (10 −7 M) and when the contraction reached a plateau, Ach (10 −10 to 10 −6 M) was added cumulatively to endothelium intact rings. To assess endothelium-independent relaxation, aortic rings precontracted by phenylephrine (10 −7 M) were used to construct cumulative concentration-response curves to sodium nitroprusside (Nps) (10 −10 to 10 −6 M). The magnitude of contraction induced by phenylephrine did not differ among the experimental groups at 10 −7 M. Relaxation was expressed as a percentage change from phenylephrine-contracted levels. Concentration-response curves were fitted using a non-linear interactive fitting program (Graph Pad Prism 5.0; GraphPad Software Inc., San Diego, CA, USA). Agonist potency was expressed as pD 2 (negative logarithm of the molar concentration of agonist producing 50% of the maximum response), and maximum response was expressed as Emax (maximum effect elicited by the agonist).
Angiotensin peptides quantification by high performance liquid chromatography (HPLC)
To determine plasma Ang I and Ang II concentrations, the venous blood samples were rapidly collected from vena cava in chilled glass tubes containing a mixture of potassium EDTA (25 mmol), o-phenanthroline (0.44 mmol), pepstatin A (0.12 mmol), and 4-chloromercuribenzoic acid (1 mmol). This mixture of protease inhibitors prevented the in vitro production and degradation of Ang peptides.
Angiotensin peptides were quantified using High Performance Liquid Chromatography (HPLC), as previously described (Almeida et al., 2006; Ronchi et al., 2007) . Angiotensin peptides were extracted from plasma. Calculation of angiotensin concentrations was based on a standard curve and values were expressed in pg/mL.
Immunofluorescence to assess aortic Ang II levels
Briefly, aortic tissues were vertically embedded in an optimum cutting temperature (OCT) compound and were frozen and cut in serial 4 µm sections. Unfixed cryosections were incubated in dark, at room temperature, with PBS-Triton 0.5% for 10 min followed by blocking buffer PBS-BSA 0.5% for 30 min. Then, the sections were incubated with antibody against Ang II (1:250 dilution; kindly donated by Cleveland Clinic, ACOLE Institute, USA) for 1 h and washed 3 times with cold PBS. After this time, anti-rabbit rhodamine conjugated secondary antibody (1:200 dilution, Chemicon) was added for 30 min and washed 3 times with cold PBS. Sections were examined using fluorescence microscopy (Leica Imaging Systems Ltd., Cambridge, England) and the image was captured at ×400. Red fluorescence represents aortic Ang II levels. The intensity of the red fluorescent signal was evaluated using ImageJ Program (Rasband, W.S., ImageJ, U. S. National Institutes of Health, Bethesda, Maryland, USA, http://imagej. nih.gov/ij/, 1997-2011). Red fluorescence intensity from 20 fields (corresponding to 20-30% of the total aortic area) selected around the vessel circumference was measured and the arithmetic mean of the fluorescence from these fields was calculated for each slide.
Assessment of vascular [NAD(P)H] oxidase activity and reactive oxygen species generation
Dihydroethidium (DHE) was used to evaluate in situ production of reactive oxygen species. Briefly, aortic tissues were embedded vertically in Tissue-tek® and criostetized. The aorta sections were incubated with DHE (10 μmol/L) as previously described (Montenegro et al., 2012) . Sections were examined with fluorescence microscopy (Leica Imaging Systems Ltd., Cambridge, England) and the image was captured at ×400. The intensity of the red fluorescent signal was evaluated using ImageJ Program (NIH -National Institute of Health) as previously described (Castro et al., 2009) . Red fluorescence intensity from 20 fields (corresponding to 20-30% of the total aortic area) selected around the vessel circumference was measured and the arithmetic mean of the fluorescence from these fields was calculated for each slide.
[NAD(P)H]-dependent superoxide anion production was measured in aortic rings from all experimental groups. Aortic rings were transferred to luminescence vials containing 1 mL of Krebs-HEPES buffer, pH 7.4. After equilibration and background counts, a non-redox cycling concentration of lucigenin (5 μmol/L) and [NAD(P)H] (300 μmol/L) were automatically added and the luminescence counts measured continuously for 15 min in a Berthold FB12 single tube luminometer at 37°C. Background signals from aortic rings were subtracted from the [NAD(P)H]-driven signals and the results were normalized for the dry weight and reported as relative light unit(RLU)/mg/min, as previously described (Montenegro et al., 2011 ).
Measurement of plasma nitrite concentrations
To examine whether drug treatment modified NO formation, plasma samples were analyzed for their nitrite contents using ozone-based reductive chemiluminescence assay, as previously detailed . Briefly, to measure nitrite concentration, 50 μl of plasma were injected into a solution of acidified triiodide, purging with nitrogen in line with a gas phase chemiluminescence NO analyzer (Sievers Model 280 NO analyzer, Boulder, CO, USA). Approximately 8 mL of triiodide solution (2 g potassium iodide and 1.3 g iodine dissolved in 40 mL water with 140 mL acetic acid) were placed in the purge vessel into which the samples were injected. The triiodide solution reduces nitrites to NO gas, which is detected by the NO analyzer. The data were analyzed using the software Origin Lab 6.1.
Statistical analysis
The results are expressed as means ± S.D. Comparisons between groups were assessed using one way and two-way analysis of variance (ANOVA) followed by the Bonferroni test or the Kruskal-Wallis (for data not normally distributed) using GraphPad Prism software. A probability value < 0.05 was considered significant.
Results
Treatment with aliskiren and/or losartan attenuated 2K1C-induced hypertension
While no significant differences in baseline SBP were observed among the eight experimental groups (Fig. 1) , 2K1C hypertension increased SBP in the hypertensive rats to more than 200 mmHg in vehicle-treated animals at the end of treatment ( Fig. 1 ; P < 0.05). Treatment with losartan, aliskiren, or the combination of drugs exerted similar antihypertensive effects ( Fig. 1 ; P < 0.05). Body weight gain during the experimental period was similar in the eight groups (P > 0.05; data not shown).
Losartan, but not aliskiren, reversed the impaired vasorelaxation endothelium-dependent found in 2K1C hypertension
To examine the effects of treatment with losartan and/or aliskiren on vascular function, rat aortic rings from sham and 2K1C rats were isolated and their functional responses to Ach were assessed in organ chamber experiments. The endothelial cell-dependent vasorelaxation induced by Ach was not affected by any treatment in the sham groups ( Fig. 2A ; P > 0.05). However, 2K1C-hypertension decreased the vasorelaxation induced by Ach by approximately one third as compared to sham-operated rats ( Fig. 2A ; P < 0.05). On the other hand, while losartan alone or combined with aliskiren completely reversed the impaired response to Ach in 2K1C rats ( Fig. 2B-C ; P < 0.05), treatment with aliskiren alone exerted minor, non-significant effects ( Fig. 2B-C ; P > 0.05).
No significant differences were found in the aortic responses to sodium nitroprusside when 2K1C hypertensive rats were compared with Sham rats. In addition, drug treatments had no effects on the responses to this NO-donor drug ( Fig. 2E-H ; P > 0.05).
3.3. Aliskiren and/or losartan treatment decreased plasma Ang I and Ang II concentrations, but only losartan diminished aortic Ang II levels in hypertensive rats
We found significantly lower plasma Ang I levels in sham rats treated with aliskiren and in 2K1C hypertensive rats treated with aliskiren or with the combination of drugs as compared with their respective vehicle-treated groups ( Fig. 3A; all P < 0.05). Importantly, treatment with aliskiren alone or combined with losartan significantly decreased plasma Ang II concentrations in sham and in 2K1C hypertensive rats ( Fig. 3B ; P < 0.05), whereas treatment with losartan alone had no effects on Ang II plasma concentrations ( Fig. 3B ; P > 0.05).
To further examine the effects of treatments on Ang II levels, we (n = 6-10 per group). *P < 0.05 versus Sham groups (panels A and C), # P < 0.05 for the 2K1C group versus 2K1C+LOS or 2K1C+ALK/LOS (panels B and C). assessed Ang II levels in aortic tissue. Confirming Ang II levels in plasma, we found that treatment with losartan alone or combined with aliskiren abolished 2K1C-induced increases in aortic Ang II concentrations assessed in the aortic media layer ( Fig. 3C-D ; P < 0.05), whereas monotherapy with aliskiren exerted no such effects ( Fig. 3C-D ; P > 0.05).
Losartan, but not aliskiren, reversed hypertension-induced oxidative stress
Renovascular hypertension significantly enhanced reactive oxygen species levels and [NAD(P)H] superoxide anion generation in the thoracic aortas from 2K1C rats when compared to sham rats (Fig. 4A-B and Fig. 5 , respectively; P < 0.05). While treatment with losartan alone or combined with aliskiren abolished both increased aortic reactive oxygen species production ( Fig. 4A-B ; P < 0.05) and hypertensioninduced increases in aortic [NAD(P)H] superoxide generation (Fig. 4A-B and Fig. 5 , respectively; P < 0.05), treatment with aliskiren alone exerted no such effect (Fig. 4A-B and Fig. 5 , respectively; P > 0.05).
Treatment with losartan enhanced plasma nitrite concentration in 2K1C rats
To assess the effects of drug treatments on NO formation, we measured nitrite concentrations in plasma samples. While no significant differences were found in plasma nitrite concentrations in sham groups ( Fig. 6 ; P > 0.05), treatment with losartan alone or combined with Fig. 4 . Effects of treatment with aliskiren and/or losartan on vascular reactive oxygen species production in 2K1C hypertensive rats. Panel A shows representative photomicrographs (x400) with red fluorescence of dihydroethidium (DHE)-aortic cryosections (5-7 per group). Panel B shows the quantification of aortic red fluorescence in each experimental group (5-7 per group). Data are shown as mean ± S.D. *P < 0.05 versus Sham (Vehicle); # P < 0.05 versus 2K1C (Vehicle). A. Martins-Oliveira et al. European Journal of Pharmacology 821 (2018) 97-104 aliskiren increased significantly the plasma nitrite concentrations in 2K1C hypertensive rats ( Fig. 6 ; P < 0.05). In contrast, treatment with aliskiren alone exerted no such effects ( Fig. 6 ; P > 0.05).
Discussion
This is the first study to show the lack of effect of aliskiren in preventing hypertension-induced vascular dysfunction, increased oxidative stress and aortic Ang II production. Another interesting finding is that blocking AT 1 receptor signaling with losartan attenuated the increases in aortic Ang II levels and decreased vascular superoxide production in hypertensive rats, possibly increasing endogenous NO bioavailability and, therefore, contributing to reversal of impaired acetylcholine-induced vasorelaxation. On the other hand, aliskiren did not improve the effects exerted by losartan. Thus, we show here that inhibiting AT 1 receptors is more relevant than renin inhibition to prevent the vascular alterations induced by 2K1C hypertension. These findings expand previous findings from our group showing that although losartan and aliskiren exerted similar antihypertensive effects in 2K1C hypertension, only losartan prevented the activation of vascular profibrotic mechanisms, matrix metalloproteinase-2 upregulation, and the vascular hypertrophy associated with vascular remodeling in hypertension (Martins-Oliveira et al., 2013) . Interestingly, aliskiren did not enhance the protective effects exerted by losartan. While we did not examine the effects on vascular function in that study (Martins-Oliveira et al., 2013) , we now show how losartan and aliskiren affect vascular oxidative stress and angiontensin I and II vascular concentrations, which may help to explain alterations in vascular function associated with 2K1C hypertension and drug effects.
Clinical and experimental studies have consistently shown that aliskiren or AT 1 receptor antagonists promote similar reductions in blood pressure (Jensen et al., 2008; Moniwa et al., 2013) . In agreement with this idea, we found that both aliskiren and losartan exerted comparable antihypertensive effects when given at equipotent doses. However, in contrast to previous clinical findings (Oparil et al., 2007) , our results showed that the combination of both drugs did not provide additional effects on blood pressure-lowering in 2K1C rats, confirming our previous findings (Martins-Oliveira et al., 2013).
Impaired endothelium-dependent vasorelaxation has been clearly shown in 2K1C hypertension , and this functional vascular alteration is attributable, at least in part, to increased formation of vascular reactive oxygen species resulting from increased [NAD(P)H] oxidase activity, thus attenuating Ach-induced vasorelaxation in experimental models of hypertension (Castro et al., 2009; Ceron et al., 2010; Costa et al., 2009) . Consistent with this idea, we found that treatment with losartan attenuated hypertension-induced increases in vascular reactive oxygen species production, and this response may be associated with antioxidant effects of losartan, thus contributing to improve NO-mediated vasorelaxation in 2K1C rats. These results agree with previous findings showing improved Ach-induced vascular relaxation after treatment with AT 1 receptor antagonist (Takai et al., 2013 (Takai et al., , 2009 .
While losartan completely blunted 2K1C hypertension-induced increases in vascular superoxide anions levels, aliskiren apparently failed to prevent this response in the present study. Indeed, we found a minor trend for antioxidant effects with aliskiren, which were not statistically significant (Fig. 4) . However, using a similar rodent model of hypertension, Mengal et al. (2016) showed antioxidant effects of aliskiren, and these findings agree with those reported by others (Fukushima et al., 2016; Imanishi et al., 2008; Rashikh et al., 2013) . These apparent discrepancies between studies could be explained by differences in the methods used to assess oxidative stress, in the daily doses used, or in pathophysiological mechanisms involved in the different animal models. The lack of significant antioxidant effects with aliskiren treatment suggests that renin inhibition exerted no significant effects on intracellular events associated with vascular reactive oxygen species production and endothelial dysfunction induced by 2K1C hypertension. In contrast, the antioxidant effects of AT 1 receptor antagonist are consistent with the suggestion that AT 1 receptor signaling is critically involved with activation of the vascular reactive oxygen species production by [NAD(P)H] oxidase enzyme.
In spite of the lack of significant effects of aliskiren on many parameters assessed here, we found lower plasma Ang I concentrations after treatment with aliskiren, which is consistent with decreased plasma renin activity after aliskiren treatment. Moreover, aliskiren, either when used as monotherapy or associated with losartan, decreased plasma Ang II concentrations, thus confirming previous clinical (Morishita et al., 2012; Virdis et al., 2012) and experimental (Rakusan et al., 2010) findings. This effect may have contributed, at least in part, to its blood pressure-lowering effects in 2K1C rats. In contrast, the less evident effects produced by losartan on circulating Ang I and II levels may be associated with low plasma renin activity usually found during the chronic phase of 2K1C hypertension, as previously described (Okamura et al., 1986) . Interestingly, while losartan completely abolished the increases in aortic Ang II levels, aliskiren did not prevent this alteration, thus suggesting that aliskiren exerts different effects on plasmatic and tissue activity of the renin-angiotensin system. In addition, we found apparently higher plasma angiotensin II concentrations in the hypertensive rats treated with the combination of aliskiren and losartan as compared with those treated with aliskiren alone (Fig. 3B ). Although this difference is not statistically significant, we could speculate that losartan may have stimulated increases in angiotensin II levels not prevented by co-treatment aliskiren. The same mechanism may be involved in apparently higher plasma angiotensin I concentrations in the Sham-operated rats treated with the combination of aliskiren and losartan as compared with those treated with aliskiren alone (Fig. 3A) . However, further studies should be carried out to clarify those issues.
Several experimental studies showed that [NAD(P)H] oxidase plays an important role in the vascular redox alterations found in 2K1C hypertension . The increased lucigenin-derived chemiluminescence reported here suggests that 2K1C hypertension increases aortic superoxide generation as a result of [NAD(P)H] oxidase activation. We found that losartan combined with aliskiren abolished the increases in aortic reactive oxygen species production and [NAD(P) H] oxidase activation. While losartan alone exerted similar effects to those found with the combination of drugs, it is interesting to notice that aliskiren alone only tended to exert such effects. These findings are consistent with 2K1C hypertension-induced [NAD(P)H] oxidase activation and superoxide generation mediated by activation of AT 1 receptors, which is prevented by losartan but not by aliskiren treatment. The lack of major effects of aliskiren on vascular Ang II levels may explain why this drug was not able to prevent 2K1C-hypertension-induced increases in vascular oxidative stress. For the same reason, the lack of significant antioxidant effects of aliskiren may explain why this drug was not able to prevent hypertension-induced endothelial dysfunction, as revealed by impaired responses to acetylcholine.
The increases in plasma nitrite that we found in the present study support the idea that treatment with losartan, but not aliskiren, enhanced NO bioavailability in hypertensive rats. This suggestion is based on previous studies showing that plasma nitrite strongly reflect constitutive nitric oxide synthase activity in mammals (Kleinbongard et al., 2003) . It is clearly possible that increased oxidative stress decreases NO bioavailability, and therefore it is very interesting to notice that we found increased plasma nitrite in those hypertensive groups of animals treated with losartan (but not aliskiren), which exerted antioxidant effects. This might result of combined effects of losartan attenuating AT 1 receptor signaling, which activates vascular [NAD(P)H] oxidase, and antioxidant responses to nitrite itself, as previously shown (Amaral et al., 2015; Montenegro et al., 2011 Montenegro et al., , 2012 .
This study has some limitations that should be taken into consideration. First, we have not assessed dose-dependent effects of aliskiren, which could help us to distinguish between plasma and vascular effects of aliskiren. However, it is important to notice that the dose of aliskiren used in the present study inhibited plasma renin activity by 50-80% and exerted major antihypertensive effects in previous studies by us (Martins-Oliveira et al., 2013) and others (Nussberger et al., 2008) . Moreover, both losartan and aliskiren exerted significant and similar antihypertensive effects in the present study, thus suggesting that the dose of aliskiren was effective. Second, we have not measured renin activity, which might be important, particularly in rats treated with aliskiren. However, the very low Ang II concentrations that we found in plasma from aliskiren-treated hypertensive rats suggest that aliskiren really inhibited renin activity, as we have previously shown in our previous study (Martins-Oliveira et al., 2013) . It is possible that aliskiren may have failed to fully inhibit aortic renin activity in 2K1C rats, thus preventing it from improving the increased vascular oxidative stress and dysfunction caused by hypertension. Third, although we have measured angiontensin I and II in this study, we have not examined other possible alterations in local renin-angiotensin system and alternative routes involved in angiotensin production and metabolism such as chymase (Urata et al., 1990) , which could help to explain the findings reported in this study. Moreover, we have not measured tissue concentrations of the heptapeptide Ang-(1-7), which may prevent Ang II-stimulated superoxide production (Polizio et al., 2007) and therefore affect the responses to the drugs used in the present study.
In conclusion, our findings show that antihypertensive effects of aliskiren are not associated with prevention of hypertension-induced vascular oxidative stress and endothelial dysfunction. In contrast, treatment with losartan lowers blood pressure and promotes vascular antioxidant effects that may result in improved vascular function. Together, our findings suggest that direct renin inhibition is not enough to prevent reactive oxygen species generation and vascular dysfunction in hypertension.
